Healthcare Industry News: Mazor Robotics
News Release - December 17, 2013
Baptist Medical Center Jacksonville (FL) Acquires a Second Renaissance System from Mazor RoboticsCAESAREA, Israel--(Healthcare Sales & Marketing Network)--Mazor Robotics Ltd. (TASE: MZOR; NASDAQCM: MZOR), the developer of Renaissance™, an innovative surgical guidance system and its complementary products, announced today that Baptist Medical Center Jacksonville (FL) has purchased its second Renaissance system. Baptist Jacksonville, which was recently ranked the number one hospital in the region by US News & World Report, purchased its first Renaissance system in March of this year.
“Baptist Jacksonville provides the highest level of medical and surgical care, and we believe in pairing the latest technologies with highly personalized care for the patient and family,” commented Michael Mayo FACHE, President of Baptist Medical Center Jacksonville. “Our implementation of the Renaissance system reflected that philosophy and thanks to the teamwork of our physicians and staff, the results have exceeded our expectations. We look forward to adding our second system as soon as possible.”
Baptist Jacksonville is a flagship hospital of Baptist Health of Northeast Florida, which includes five hospitals as well as outpatient centers, home health, rehabilitation, primary and specialty physician offices. It has been serving families throughout the region with high-quality, comprehensive care for every stage of life since its founding in 1955. For more information, visit www.baptistjax.com
Mazor Robotics (TASE: MZOR; NASDAQCM: MZOR) is dedicated to the development and marketing of innovative surgical robots and complementary products that provide a safer surgical environment for patients, surgeons, and operating room staff. Mazor Robotics’ flagship product, Renaissance™, is a state-of-the-art surgical robotic system that enables surgeons to conduct spine surgeries in an accurate and secure manner. Mazor Robotics systems have been successfully used in the placement of over 35,000 implants worldwide. Numerous peer-reviewed publications and presentations at leading scientific conferences have validated the accuracy, usability, and clinical advantages of Mazor Robotics technology. For more information, the content of which is not part of this press release, please visit www.mazorrobotics.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the clinical and economic benefits of Renaissance, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor's current expectations and projections about future events. There are important factors that could cause Mazor's actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor's filings with the Securities and Exchange Commission (SEC)., including those discussed under the heading "Risk Factors" in Mazor’s registration statement on Form F-1 and in subsequent filings with the SEC. For more details, refer to Mazor's SEC filings and the amendments thereto. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.
Source: Mazor Robotics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.